Can the breast screening appointment be used to provide risk assessment and prevention advice?

D Gareth Evans, Anthony Howell, D Gareth Evans, Anthony Howell

Abstract

Breast cancer risk is continuing to increase across all societies with rates in countries with traditionally lower risks catching up with the higher rates in the Western world. Although cure rates from breast cancer have continued to improve such that absolute numbers of breast cancer deaths have dropped in many countries despite rising incidence, only some of this can be ascribed to screening with mammography, and debates over the true value of population-based screening continue. As such, enthusiasm for risk-stratified screening is gaining momentum. Guidelines in a number of countries already suggest more frequent screening in certain higher-risk (particularly, familial) groups, but this could be extended to assessing risks across the population. A number of studies have assessed breast cancer risk by using risk algorithms such as the Gail model, Tyrer-Cuzick, and BOADICEA (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm), but the real questions are when and where such an assessment should take place. Emerging evidence from the PROCAS (Predicting Risk Of Cancer At Screening) study is showing not only that it is feasible to undertake risk assessment at the population screening appointment but that this assessment could allow reduction of screening in lower-risk groups in many countries to 3-yearly screening by using mammographic density-adjusted breast cancer risk.

References

    1. CR-UK, CancerStats Incidence - UK. Cancer Research UK 2011. . Accessed 30 Dec 2014.
    1. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643–6. doi: 10.1126/science.1088759.
    1. Tryggvadottir L, Sigvaldason H, Olafsdottir GH, Jonasson JG, Jonsson T, Tulinius H, et al. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000. J Natl Cancer Inst. 2006;98:116–22. doi: 10.1093/jnci/djj012.
    1. Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in the service setting: higher risk in recent birth cohorts. BMC Cancer. 2008;8:155. doi: 10.1186/1471-2407-8-155.
    1. Marmot M, Independent UK Panel on Breast Cancer Screening. Altman G, Cameron DA, Dewar JA, Thompson SG, Wilcox M. Independent UK Panel on Breast Cancer Screening replies to Michael Baum. BMJ. 2013;346:f873. doi: 10.1136/bmj.f873.
    1. National Collaborating Centre for Cancer. Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. Update of clinical guideline 14 and 41. Clinical guideline 164. London: NCCC, 2013. . Accessed 23 July 2013.
    1. Evans DG, Graham J, O’Connell S, Arnold S, Fitzsimmons D. Familial breast cancer: summary of updated NICE guidance. BMJ. 2013;346:f3829. doi: 10.1136/bmj.f3829.
    1. Pharoah PD, Sewell B, Fitzsimmons D, Bennett HS, Pashayan N. Cost effectiveness of the NHS breast screening programme: life table model. BMJ. 2013;346:f2618. doi: 10.1136/bmj.f2618.
    1. Schousboe JT, Kerlikowske K, Loh A, Cummings SR. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med. 2011;155:10–20. doi: 10.7326/0003-4819-155-1-201107050-00003.
    1. de Bock GH, Vermeulen KM, Jansen L, Oosterwijk JC, Siesling S, Dorrius MD, et al. Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness. Br J Cancer. 2013;30(108):1579–86. doi: 10.1038/bjc.2013.149.
    1. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, et al. Long-term results of tamoxifen prophylaxis for breast cancer 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99:272–82. doi: 10.1093/jnci/djk049.
    1. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011;12:496–503. doi: 10.1016/S1470-2045(11)70030-4.
    1. Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, Decensi A, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381:1827–34. doi: 10.1016/S0140-6736(13)60140-3.
    1. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila) 2010;3:696–706. doi: 10.1158/1940-6207.CAPR-10-0076.
    1. Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, et al. Evaluation of breast cancer risk assessment packages in the Family History Evaluation and Screening Programme. J Med Genet. 2003;40:807–14. doi: 10.1136/jmg.40.11.807.
    1. Pashayan N, Duffy SW, Chowdhury S, Dent T, Burton H, Neal DE, et al. Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer. 2011;104:1656–63. doi: 10.1038/bjc.2011.118.
    1. Leggatt V, Mackay J, Yates JR. Evaluation of questionnaire on cancer family history in identifying patients at increased genetic risk in general practice. BMJ. 1999;319:757–8. doi: 10.1136/bmj.319.7212.757.
    1. Johnson N, Lancaster T, Fuller A, Hodgson SV. The prevalence of a family history of cancer in general practice. Fam Pract. 1995;12:287–9. doi: 10.1093/fampra/12.3.287.
    1. Eccles DM, Evans DG, Mackay J. Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. J Med Genet. 2000;37:203–9. doi: 10.1136/jmg.37.3.203.
    1. van Asperen CJ, Tollenaar RA, Krol-Warmerdam EM, Blom J, Hoogendoorn WE, Seynaeve CM, et al. Possible consequences of applying guidelines to healthy women with a family history of breast cancer. Eur J Hum Genet. 2003;11:633–67. doi: 10.1038/sj.ejhg.5201021.
    1. de Bock GH, Jacobi CE, Seynaeve C, Krol-Warmerdam EM, Blom J, van Asperen CJ, et al. A family history of breast cancer will not predict female early onset breast cancer in a population-based setting. BMC Cancer. 2008;8:203. doi: 10.1186/1471-2407-8-203.
    1. Amir E, Freedman OC, Seruga B, Evans DG. Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst. 2010;102:680–91. doi: 10.1093/jnci/djq088.
    1. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879–86. doi: 10.1093/jnci/81.24.1879.
    1. Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91:1541–48. doi: 10.1093/jnci/91.18.1541.
    1. Euhus DM, Leitch AM, Huth JF, Peters GN. Limitations of the Gail model in the specialized breast cancer risk assessment clinic. Breast. 2002;8:23–7. doi: 10.1046/j.1524-4741.2002.08005.x.
    1. Claus EB, Risch N, Thompson WD. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat. 1993;28:115–20. doi: 10.1007/BF00666424.
    1. Parmigiani G, Berry DA, Aquilar O. Determining carrier probabilities for breast cancer susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998;62:145–8. doi: 10.1086/301670.
    1. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer. 2008;98:2015. doi: 10.1038/sj.bjc.6604411.
    1. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23:1111–30. doi: 10.1002/sim.1668.
    1. Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MR, et al. Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med. 2002;347:886–94. doi: 10.1056/NEJMoa013390.
    1. Pankow JS, Vachon CM, Kuni CC, King RA, Arnett DK, Grabrick DM, et al. Genetic analysis of mammographic breast density in adult women: evidence of a gene effect. J Natl Cancer Inst. 1997;89:549–56. doi: 10.1093/jnci/89.8.549.
    1. Santen R, Boyd N, Chlebowski RT, Cummings S, Cuzick J, Dowsett M, et al. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer. 2007;14:169–87. doi: 10.1677/ERC-06-0045.
    1. Barlow WE, White E, Ballard-Barbash R, Vacek PM, Titus-Ernstoff L, Carney PA, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst. 2006;98:1204–14. doi: 10.1093/jnci/djj331.
    1. Chen J, Pee D, Ayyagari R, Graubard B, Schairer C, Byrne C, et al. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst. 2006;98:1215–26. doi: 10.1093/jnci/djj332.
    1. Howell A, Anderson AS, Clarke RB, Duffy SW, Evans DG, et al. Risk determination and prevention of breast cancer. Breast Cancer Res. 2014;16:446. doi: 10.1186/s13058-014-0446-2.
    1. Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M. Genetic susceptibility to breast cancer. Mol Oncol. 2010;4:174–91. doi: 10.1016/j.molonc.2010.04.011.
    1. Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush MJ, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet. 2015;47:373–80. doi: 10.1038/ng.3242.
    1. Mealiffe ME, Stokowski RP, Rhees BK, Prentice RL, Pettinger M, Hinds DA. Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. J Natl Cancer Inst. 2010;102:1618–27. doi: 10.1093/jnci/djq388.
    1. McCarthy A, Keller B, Kontos D, Boghossian L, McGuire E, Bristol M, et al. The use of the Gail model, body mass index and SNPs to predict breast cancer among women with abnormal (BI-RADS 4) mammograms. Breast Cancer Res. 2015;17:1. doi: 10.1186/s13058-014-0509-4.
    1. Weisstock CR, Rajapakshe R, Bitgood C, McAvoy S, Gordon PB, Coldman AJ, et al. Assessing the breast cancer risk distribution for women undergoing screening in British Columbia. Cancer Prev Res (Phila) 2013;6:1084–92. doi: 10.1158/1940-6207.CAPR-13-0027.
    1. Powell M, Jamshidian F, Cheyne K, Nititham J, Prebil LA, Ereman R. Assessing breast cancer risk models in Marin County, a population with high rates of delayed childbirth. Clin Breast Cancer. 2014;14:212–220.e1. doi: 10.1016/j.clbc.2013.11.003.
    1. Quante AS, Whittemore AS, Shriver T, Strauch K, Terry MB. Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance. Breast Cancer Res. 2012;14:R144. doi: 10.1186/bcr3352.
    1. Evans DG, Warwick J, Astley SM, Stavrinos P, Sahin S, Ingham SL, et al. Assessing individual breast cancer risk within the UK National Health Service Breast Screening Programme: a new paradigm for cancer prevention. Cancer Prev Res (Phila) 2012;5:943–51. doi: 10.1158/1940-6207.CAPR-11-0458.
    1. Evans DG, Brentnall AR, Harvie M, Dawe S, Sergeant J, Stavrinos P, et al. Breast cancer risk in young women in the National Breast Screening Programme: implications for applying NICE guidelines for additional screening and chemoprevention. Cancer Prev Res. 2014;7:993–1001. doi: 10.1158/1940-6207.CAPR-14-0037.
    1. Li J, Foo JN, Schoof N, Varghese JS, Fernandez-Navarro P, Gierach GL, et al. Large-scale genotyping identifies a new locus at 22q13.2 associated with female breast size. J Med Genet. 2013;50:666–73. doi: 10.1136/jmedgenet-2013-101708.
    1. Colditz GA, Bohlke K. Priorities for the primary prevention of breast cancer. CA Cancer J Clin. 2014;64:186–94. doi: 10.3322/caac.21225.
    1. Harvie M, Howell A. Energy restriction and the prevention of breast cancer. Proc Nutr Soc. 2012;71:263–75. doi: 10.1017/S0029665112000195.
    1. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78. doi: 10.1016/S0140-6736(08)60269-X.
    1. Harvie M, Howell A, Vierkant RA, Kumar N, Cerhan JR, Kelemen LE, et al. Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women’s health study. Cancer Epidemiol Biomarkers Prev. 2005;14:656–61. doi: 10.1158/1055-9965.EPI-04-0001.
    1. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA. 2006;296:193–201. doi: 10.1001/jama.296.2.193.
    1. Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath CW, Jr, et al. Alcohol, tobacco and breast cancer - collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer. 2002;87:1234–45. doi: 10.1038/sj.bjc.6600596.
    1. Chen WY, Rosner B, Hankinson SE, Colditz GA, Willett WC. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA. 2011;306:1884–90. doi: 10.1001/jama.2011.1590.
    1. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;64:2381–91. doi: 10.1056/NEJMoa1103507.
    1. Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383:1041–8. doi: 10.1016/S0140-6736(13)62292-8.
    1. Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16:67–75. doi: 10.1016/S1470-2045(14)71171-4.
    1. Donnelly LS, Evans DG, Wiseman J, Fox J, Greenhalgh R, Affen J, et al. Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. Br J Cancer. 2014;110:1681–7. doi: 10.1038/bjc.2014.109.
    1. Collaborative Group on Hormonal Factors in Breast Cancer Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13:1141–51. doi: 10.1016/S1470-2045(12)70425-4.
    1. MacMahon B, Cole P, Lin TM, Lowe CR, Mirra AP, Ravnihar B, et al. Age at first birth and breast cancer risk. Bull World Health Organ. 1970;43:209–21.
    1. Beral V, Million Women Study Collaborators Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419–27. doi: 10.1016/S0140-6736(03)14596-5.
    1. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347:1713–2. doi: 10.1016/S0140-6736(96)90806-5.
    1. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002;360:187–95. doi: 10.1016/S0140-6736(02)09454-0.
    1. Brown SB, Hankinson SE. Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers. Steroids. 2014;pii:S0039-128X(14)00306–7.
    1. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer. 1985;55:2698–708. doi: 10.1002/1097-0142(19850601)55:11<2698::AID-CNCR2820551127>;2-A.
    1. Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst. 1995;87:670–5. doi: 10.1093/jnci/87.9.670.
    1. Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer. 1997;71:800–9. doi: 10.1002/(SICI)1097-0215(19970529)71:5<800::AID-IJC18>;2-B.
    1. Hemminki K, Vaittinen P. Male breast cancer: risk to daughters. Lancet. 1999;353:1186–7. doi: 10.1016/S0140-6736(05)74408-1.
    1. Mavaddat N, Pharoah PD, Michailidou K, Tyrer J, Brook MN, Bolla MK, et al. Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst. 2015;107. pii:djv036. doi: 10.1093/jnci/djv036.
    1. Evans DG, Howell A. Breast cancer risk-assessment models. Breast Cancer Res. 2007;9:213. doi: 10.1186/bcr1750.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel